ClearPoint Neuro (CLPT) Expected to Post Quarterly Earnings on Wednesday

ClearPoint Neuro (NASDAQ:CLPT) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $12.30 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.09). ClearPoint Neuro had a negative net margin of 81.76% and a negative return on equity of 188.09%. The firm had revenue of $10.88 million during the quarter, compared to analyst estimates of $12.73 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. On average, analysts expect ClearPoint Neuro to post ($1.22) EPS for the current fiscal year and ($1.16) EPS for the next fiscal year.

ClearPoint Neuro Trading Up 1.9%

ClearPoint Neuro stock traded up $0.17 during midday trading on Tuesday, reaching $9.21. 25,665 shares of the stock traded hands, compared to its average volume of 709,651. The firm has a market cap of $280.90 million, a PE ratio of -7.73 and a beta of 1.29. The company has a current ratio of 4.74, a quick ratio of 3.89 and a debt-to-equity ratio of 4.66. The company has a 50-day simple moving average of $12.91 and a two-hundred day simple moving average of $13.10. ClearPoint Neuro has a 12-month low of $8.27 and a 12-month high of $27.27.

Analyst Ratings Changes

CLPT has been the topic of several recent research reports. Lake Street Capital set a $25.00 target price on shares of ClearPoint Neuro in a research note on Tuesday, August 4th. Stifel Nicolaus set a $22.00 price target on shares of ClearPoint Neuro in a research report on Tuesday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $25.67.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes platforms for minimally invasive procedures involving the brain. Its technology is designed to help physicians plan, navigate and deliver treatments with real-time magnetic resonance imaging (MRI) guidance, supporting more precise access to targeted areas of the brain.

The company’s principal product is the ClearPoint Neuro Navigation System, which uses specialized software, instruments and accessories to guide neurosurgical procedures inside an MRI scanner.